<DOC>
	<DOCNO>NCT00738335</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes necessary growth . Radiation therapy use high-energy x-ray kill tumor cell . Stereotactic radiosurgery may able deliver x-ray directly tumor cause less damage normal tissue . Erlotinib may make tumor cell sensitive radiation therapy . Giving erlotinib together stereotactic radiosurgery may kill tumor cell . PURPOSE : This phase I clinical trial study side effect erlotinib give together stereotactic radiosurgery see well work treat patient non-small cell lung cancer brain metastasis .</brief_summary>
	<brief_title>Stereotactic Radiosurgery Erlotinib Treating Patients With Non-Small Cell Lung Cancer Brain Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine acute well long-term toxicity ( especially grade III neurotoxicity ) concurrent erlotinib hydrochloride single-fraction radiosurgery patient non-small cell lung cancer ( NSCLC ) brain metastasis . Secondary - To determine freedom progression detect lesion ( i.e. , radiosurgically treat untreated ) rate response radiosurgically treated lesion patient receive concurrent erlotinib hydrochloride radiosurgery compare historical control treat gamma knife radiosurgery alone UCSF . - To measure rate freedom CNS progression patient 1 year post treatment . - To assess cerebrospinal fluid ( CSF ) distribution erlotinib hydrochloride measure erlotinib hydrochloride major metabolite , OSI-420 , plasma CSF 4 day initial erlotinib hydrochloride administration radiosurgery , 4 week stereotactic radiosurgery ( optional ) . - To perform CSF serum biomarker analysis NSCLC use 2-dimensional liquid chromatography mass spectrometry ( 2D-LC/MS ) . - To determine incidence subclinical leptomeningeal disease patient assign gamma-knife treatment exhibit sign symptoms carcinomatous meningitis . OUTLINE : Patients receive oral erlotinib hydrochloride daily least 7 day . Patients undergo stereotactic radiosurgery day 0 . Beginning day radiosurgery , patient receive erlotinib hydrochloride daily 4 week absence disease progression unacceptable toxicity . After completion study therapy , patient may continue receive erlotinib hydrochloride discretion oncologist . Patients undergo cerebrospinal fluid ( CSF ) blood sample collection baseline ( least 4 day start erlotinib hydrochloride prior radiosurgery ) pharmacokinetic biomarker correlative study . Samples analyze concentration erlotinib hydrochloride 2-dimensional-liquid chromatography/mass spectrometry antithrombin enzyme-linked immunosorbent assay . After completion study therapy , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer ( NSCLC ) meeting follow criterion : Fewer 5 intraparenchymal brain metastasis gadoliniumenhanced MRI meeting follow criterion : Maximum diameter ≤ 4.0 cm If multiple lesion present one lesion &gt; 3.0 cm , remain lesion must ≤ 3.0 cm maximum diameter No metastasis within 3 mm optic nerve optic chiasm portion optic nerve chiasm would receive &gt; 9 Gy radiosurgery No metastases brainstem , midbrain , pons , medulla No prior complete resection single brain metastasis know brain metastasis Subtotal resection allow provide residual disease ≤ 4.0 cm maximum diameter No clinical radiographic evidence unstable systemic progression ( study lesion [ ] ) within past month Patients brain metastases initial presentation require 1 month scan document stable disease Isolated brain metastasis stable systemic disease allow No leptomeningeal metastasis MRI and/or positive cerebrospinal fluid cytology PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Life expectancy ≥ 3 month ANC &gt; 1,000/mm³ Platelet count &gt; 100,000/mm³ Hemoglobin &gt; 10 g/dL PT PTT normal AST &lt; 2 time upper limit normal ( ULN ) Alkaline phosphatase &lt; 2 time ULN Total bilirubin &lt; 2 time ULN Lactic dehydrogenase &lt; 2 time ULN Serum creatinine &lt; 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 2 week completion study therapy Neurologic function status 02 No history allergic reaction attribute compound similar chemical biologic composition erlotinib hydrochloride No contraindication MRI ( e.g. , cardiac pacemaker ) No absolute contraindication lumbar puncture PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior systemic therapy allow No prior cranial radiotherapy Prior radiotherapy noncranial site allow More 1 week since prior intrathecal chemotherapy prior treatment leptomeningeal carcinoma No concurrent systemic therapy Prior current erlotinib hydrochloride treatment systemic disease allow provided systemic disease progress erlotinib hydrochloride No concurrent enzymeinducing anticonvulsant If patient enzymeinducing anticonvulsant ( e.g. , phenytoin , carbamazepine , phenobarbital ) , agent must convert nonenzymeinducing anticonvulsant start erlotinib hydrochloride treatment No concurrent CYP3A4 inhibitor inducer ( e.g. , Hypericum perforatum [ St. John wort ] ketoconazole ) No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>tumor metastatic brain</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>